AR and prostate carcinoma: Currently used AR antagonists, including hydroxyflutamide, bicalutamide, and enzalutamide, target the androgen‐binding site of the receptor and compete with endogenous testosterone or DHT.[26] However, AR mutations at this ligand‐binding site are associated with poor prognosis and resistance to conventional prostate cancer treatments.[26] These spontaneous mutations often arise in patients after long‐term treatment with drugs indicated in Figure 5A, leading to expanded binding specificity for AR and an increase in AR signaling.[27]